174 related articles for article (PubMed ID: 32748250)
1. Prognostic factors in patients with locally advanced or borderline resectable pancreatic ductal adenocarcinoma: chemotherapy vs. chemoradiotherapy.
Kim SS; Lee S; Lee HS; Bang S; Park MS
Abdom Radiol (NY); 2021 Feb; 46(2):655-666. PubMed ID: 32748250
[TBL] [Abstract][Full Text] [Related]
2. How Does Chemoradiotherapy Following Induction FOLFIRINOX Improve the Results in Resected Borderline or Locally Advanced Pancreatic Adenocarcinoma? An AGEO-FRENCH Multicentric Cohort.
Pietrasz D; Turrini O; Vendrely V; Simon JM; Hentic O; Coriat R; Portales F; Le Roy B; Taieb J; Regenet N; Goere D; Artru P; Vaillant JC; Huguet F; Laurent C; Sauvanet A; Delpero JR; Bachet JB; Sa Cunha A
Ann Surg Oncol; 2019 Jan; 26(1):109-117. PubMed ID: 30362063
[TBL] [Abstract][Full Text] [Related]
3. Comparison of preoperative concurrent chemoradiotherapy with chemotherapy alone in patients with locally advanced siewert II and III adenocarcinoma of the esophagogastric junction.
Ge X; Zhao Q; Song Y; Li J; Liu M; Bai W; Qiao X
Eur J Surg Oncol; 2018 Apr; 44(4):502-508. PubMed ID: 29395438
[TBL] [Abstract][Full Text] [Related]
4. Predictors of Resectability and Survival in Patients With Borderline and Locally Advanced Pancreatic Cancer who Underwent Neoadjuvant Treatment With FOLFIRINOX.
Michelakos T; Pergolini I; Castillo CF; Honselmann KC; Cai L; Deshpande V; Wo JY; Ryan DP; Allen JN; Blaszkowsky LS; Clark JW; Murphy JE; Nipp RD; Parikh A; Qadan M; Warshaw AL; Hong TS; Lillemoe KD; Ferrone CR
Ann Surg; 2019 Apr; 269(4):733-740. PubMed ID: 29227344
[TBL] [Abstract][Full Text] [Related]
5. Improved Clinical Staging System for Localized Pancreatic Cancer Using the ABC Factors: A TAPS Consortium Study.
Dekker EN; van Dam JL; Janssen QP; Besselink MG; DeSilva A; Doppenberg D; van Eijck CHJ; Nasar N; O'Reilly EM; Paniccia A; Prakash LR; Tzeng CD; Verkolf EMM; Wei AC; Zureikat AH; Katz MHG; Groot Koerkamp B;
J Clin Oncol; 2024 Apr; 42(12):1357-1367. PubMed ID: 38315954
[TBL] [Abstract][Full Text] [Related]
6. Preoperative independent prognostic factors in patients with borderline resectable pancreatic ductal adenocarcinoma following curative resection: the neutrophil-lymphocyte and platelet-lymphocyte ratios.
Asari S; Matsumoto I; Toyama H; Shinzeki M; Goto T; Ishida J; Ajiki T; Fukumoto T; Ku Y
Surg Today; 2016 May; 46(5):583-92. PubMed ID: 26108488
[TBL] [Abstract][Full Text] [Related]
7. Intraoperative Radiation Therapy (IORT) for Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma (BR/LA PDAC) in the Era of Modern Neoadjuvant Treatment: Short-Term and Long-Term Outcomes.
Harrison JM; Wo JY; Ferrone CR; Horick NK; Keane FK; Qadan M; Lillemoe KD; Hong TS; Clark JW; Blaszkowsky LS; Allen JN; Castillo CF
Ann Surg Oncol; 2020 May; 27(5):1400-1406. PubMed ID: 31758284
[TBL] [Abstract][Full Text] [Related]
8. Multiparametric MRI for prediction of treatment response to neoadjuvant FOLFIRINOX therapy in borderline resectable or locally advanced pancreatic cancer.
Kang JH; Lee SS; Kim JH; Byun JH; Kim HJ; Yoo C; Kim KP; Ryoo BY; Kim SC
Eur Radiol; 2021 Feb; 31(2):864-874. PubMed ID: 32813104
[TBL] [Abstract][Full Text] [Related]
9. Prognostic Impact of the Neutrophil-to-Lymphocyte Ratio in Borderline Resectable Pancreatic Ductal Adenocarcinoma Treated with Neoadjuvant Chemoradiotherapy Followed by Surgical Resection.
Kubo H; Murakami T; Matsuyama R; Yabushita Y; Tsuchiya N; Sawada Y; Homma Y; Kumamoto T; Endo I
World J Surg; 2019 Dec; 43(12):3153-3160. PubMed ID: 31549202
[TBL] [Abstract][Full Text] [Related]
10. Visual enhancement pattern during the delayed phase of enhanced CT as an independent prognostic factor in stage IV pancreatic ductal adenocarcinoma.
Fukukura Y; Kumagae Y; Higashi R; Hakamada H; Nagano H; Hidaka S; Kamimura K; Maemura K; Arima S; Yoshiura T
Pancreatology; 2020 Sep; 20(6):1155-1163. PubMed ID: 32800574
[TBL] [Abstract][Full Text] [Related]
11. Endostar improved efficacy of concurrent chemoradiotherapy with vinorelbine plus carboplatin in locally advanced lung squamous cell carcinoma patients with high serum Lp(a) concentration.
Xu H; Lv D; Meng Y; Wang M; Wang W; Zhou C; Zhou S; Chen X; Yang H
Ann Palliat Med; 2020 Mar; 9(2):298-307. PubMed ID: 32075401
[TBL] [Abstract][Full Text] [Related]
12. Locally advanced pancreatic cancer: association between prolonged preoperative treatment and lymph-node negativity and overall survival.
Kadera BE; Sunjaya DB; Isacoff WH; Li L; Hines OJ; Tomlinson JS; Dawson DW; Rochefort MM; Donald GW; Clerkin BM; Reber HA; Donahue TR
JAMA Surg; 2014 Feb; 149(2):145-53. PubMed ID: 24306217
[TBL] [Abstract][Full Text] [Related]
13. Impact of chemoradiotherapy after disease control with chemotherapy in locally advanced pancreatic adenocarcinoma in GERCOR phase II and III studies.
Huguet F; André T; Hammel P; Artru P; Balosso J; Selle F; Deniaud-Alexandre E; Ruszniewski P; Touboul E; Labianca R; de Gramont A; Louvet C
J Clin Oncol; 2007 Jan; 25(3):326-31. PubMed ID: 17235048
[TBL] [Abstract][Full Text] [Related]
14. Validation of Prognostic Radiomic Features From Resectable Pancreatic Ductal Adenocarcinoma in Patients With Advanced Disease Undergoing Chemotherapy.
Salinas-Miranda E; Khalvati F; Namdar K; Deniffel D; Dong X; Abbas E; Wilson JM; O'Kane GM; Knox J; Gallinger S; Haider MA
Can Assoc Radiol J; 2021 Nov; 72(4):605-613. PubMed ID: 33151087
[TBL] [Abstract][Full Text] [Related]
15. Comparison of Overall Survival Between Preoperative Chemotherapy and Chemoradiotherapy for Resectable Pancreatic Adenocarcinoma.
Mokdad AA; Minter RM; Yopp AC; Porembka MR; Wang SC; Zhu H; Augustine MM; Mansour JC; Choti MA; Polanco PM
J Natl Compr Canc Netw; 2018 Dec; 16(12):1468-1475. PubMed ID: 30545994
[No Abstract] [Full Text] [Related]
16. Survival Analysis in Patients with Pancreatic Ductal Adenocarcinoma Undergoing Chemoradiotherapy Followed by Surgery According to the International Consensus on the 2017 Definition of Borderline Resectable Cancer.
Hayasaki A; Isaji S; Kishiwada M; Fujii T; Iizawa Y; Kato H; Tanemura A; Murata Y; Azumi Y; Kuriyama N; Mizuno S; Usui M; Sakurai H
Cancers (Basel); 2018 Mar; 10(3):. PubMed ID: 29510561
[No Abstract] [Full Text] [Related]
17. Predictive value of baseline serum carbohydrate antigen 19-9 level on treatment effect of neoadjuvant chemoradiotherapy in patients with resectable and borderline resectable pancreatic cancer in two randomized trials.
Doppenberg D; van Dam JL; Han Y; Bonsing BA; Busch OR; Festen S; van der Harst E; de Hingh IH; Homs MYV; Kwon W; Lee M; Lips DJ; de Meijer VE; Molenaar IQ; Nuyttens JJ; Patijn GA; van Roessel S; van der Schelling GP; Suker M; Versteijne E; de Vos-Geelen J; Wilmink JW; van Eijck CHJ; van Tienhoven G; Jang JY; Besselink MG; Groot Koerkamp B;
Br J Surg; 2023 Sep; 110(10):1374-1380. PubMed ID: 37440421
[TBL] [Abstract][Full Text] [Related]
18. The clinical impact of portal venous patency ratio on prognosis of patients with pancreatic ductal adenocarcinoma undergoing pancreatectomy with combined resection of portal vein following preoperative chemoradiotherapy.
Jaseanchiun W; Kato H; Hayasaki A; Fujii T; Iizawa Y; Tanemura A; Murata Y; Azumi Y; Kuriyama N; Kishiwada M; Mizuno S; Usui M; Sakurai H; Isaji S
Pancreatology; 2019 Mar; 19(2):307-315. PubMed ID: 30738764
[TBL] [Abstract][Full Text] [Related]
19. Impact of hypofractionated and standard fractionated chemoradiation before pancreatoduodenectomy for pancreatic ductal adenocarcinoma.
Cloyd JM; Crane CH; Koay EJ; Das P; Krishnan S; Prakash L; Snyder RA; Varadhachary GR; Wolff RA; Javle M; Shroff RT; Fogelman D; Overman M; Wang H; Maitra A; Lee JE; Fleming JB; Katz MH
Cancer; 2016 Sep; 122(17):2671-9. PubMed ID: 27243381
[TBL] [Abstract][Full Text] [Related]
20. Total Neoadjuvant Therapy With FOLFIRINOX Followed by Individualized Chemoradiotherapy for Borderline Resectable Pancreatic Adenocarcinoma: A Phase 2 Clinical Trial.
Murphy JE; Wo JY; Ryan DP; Jiang W; Yeap BY; Drapek LC; Blaszkowsky LS; Kwak EL; Allen JN; Clark JW; Faris JE; Zhu AX; Goyal L; Lillemoe KD; DeLaney TF; Fernández-Del Castillo C; Ferrone CR; Hong TS
JAMA Oncol; 2018 Jul; 4(7):963-969. PubMed ID: 29800971
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
